UPDATE: (May 2019) – A new study published May 6th in the journal Annals of Internal Medicine, indicates the risk of developing “Fournier’s gangrene” from taking SGLT-2 Inhibitors is greater than initially believed. The researchers, examining information from the FDA’s Adverse Reporting System, discovered “Fournier gangrene” occurred in 55 people taking SGLT-2 Inhibitors (Invokana, Farxiga & Jardiance) between March 1, 2013, and January 31, 2019. In comparison, researchers found only 19 cases of the disease in people taking other diabetes medications between 1984 and January 31, 2019.
“Fournier’s gangrene” can cause extreme pain in the scrotum, penis, vulva, vagina, or anal areas, as well as fever and a general, overall feeling of fatigue and illness. The affected area may appear red, emit a foul odor, and become gangrenous causing tissue to die. If left untreated, “Fournier’s gangrene” can spread to the thighs, into the abdominal wall, and up to the chest. The condition is generally treated with broad-spectrum antibiotics to kill the infection, and surgery to remove dead tissue.
If you or a loved one were diagnosed with “Fournier’s gangrene” after taking Invokana, Jardiance or Farxiga, contact us online or call us at 1-866-252-3535.
UPDATE: (Aug. 2018) – The U.S. Food & Drug Administration has released an official “risk warning” regarding a rare but extremely serious, life-threatening condition associated with SGLT-2 Inhibitors, including Invokana, Jardiance, and Farxiga. “Fournier’s gangrene” is an necrotizing infection that affects the tissue, muscles, fat, nerves and blood vessels of the perineum; the area around/between the genitals and the rectum. The condition can quickly worsen and result in death.
If you or a loved one were hospitalized for renal failure, ketoacidosis, suffered a heart attack or stroke, required a leg, foot or toe amputation, or been diagnosed with “Fournier’s gangrene” while taking Invokana, Jardiance or Farxiga, contact us online or call us at 1-866-252-3535.
UPDATE: (Aug. 2018) – Another medical study has found that SGLT-2 Inhibitors like Jardiance and Farxiga significantly increase the risk a user will have to undergo a lower limb amputation compared with older drugs such as Metformin.
MedPage Today | Aug. 3, 2018 | By Kristen Monaco
Farxiga and Jardiance are part of a new class of diabetes drugs that also includes Invokana. These diabetes drugs, called SGLT2 Inhibitors, are already causing a plethora of problems with the diabetics who use them.
If you or a loved one has taken Invokana, Farxiga, or Jardiance and been hospitalized with ketoacidosis, urosepsis, kidney damage and/or renal failure, have undergone a ‘lower-limb’ amputation, or have been diagnosed with “Fournier’s gangrene”, contact us online or call 1-866-252-3535 for a free consultation.